Acetylcholinesterase inhibitor treatment for myasthenia gravis

In myasthenia gravis, antibody-mediated blockade of acetylcholine receptors at the neuromuscular junction abolishes the naturally occurring «safety factor» of synaptic transmission. Acetylcholinesterase inhibitors provide temporary symptomatic treatment of muscle weakness but there is controversy about their long-term efficacy, dosage and side effects.

Английский

Cochrane Database of Systematic Reviews. – 2014. – № 10.